PSMA PET in prostate cancer
PSMA PET imaging for staging and recurrence of prostate cancer.
Key point
PSMA-PET/CT is recommended only when PSA exceeds 0.2 μg/L, reporting should follow PSMA-RADS, and it is preferred over lymph-node dissection for staging.
From: The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease (Scand J Urol, 2026 Apr 21) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 61, 72, 85, 92, 102.
New guidelines and consensus this year
All papers from the last 12 months
948 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Multimodality imaging of high-grade prostate adenocarcinoma with diffusion MRI, PSMA PET and dual-layer spectral CT: A case reportRadiol Case Rep2026 DecPMID 42781221
- Present status of prostate cancer diagnosis, limitations, challenges, and future endeavorsAnn Med2026 DecPMID 42544420Review
- Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial dataJ Med Econ2026 DecPMID 42464573
- First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617Ann Med2026 DecPMID 42304982
- Pelvic lymph node dissection in prostate cancer: current evidence, controversies, and future directionsAnn Med2026 DecPMID 41999318Review
- Near-complete Response of Bilateral Adrenal Metastases to 177Lu-PSMA Therapy in Castration-resistant Prostate Cancer on Posttherapeutic SPECT-CT Follow UpClin Nucl Med2026 Nov 1PMID 42853992
- PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic ReviewEur Urol Open Sci2026 NovPMID 42828270Review
- Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxelCancer Treat Rev2026 NovPMID 42800445Review
- Two-year outcomes following PSMA PET and MRI guided prostate SABR with simultaneous focal boost: a brief report from the ARGOS-CLIMBER phase 1/2 trialRadiother Oncol2026 NovPMID 42744076
- Salvage therapy for radiorecurrent prostate cancer: beyond equipoise - a call for biomarker-driven stratificationTransl Oncol2026 NovPMID 42731418
More urology trends
All specialties →MRI in prostate cancer diagnosis
MRI before biopsy and in screening for prostate cancer.
Transperineal prostate biopsy
Biopsy through the perineum instead of the rectum.
Key point: Transperineal biopsy is the recommended approach when technically feasible.
Thulium fibre laser
Thulium fibre laser for stone lithotripsy and prostate surgery.
Key point: ThuFLEP and conventional HoLEP are clinically comparable, with no definitive superiority of either laser.
Male infertility
Male infertility and trends in semen quality.
Key point: Male infertility management should be couple-centered, integrating the female partner's reproductive timeline to avoid preventable delays in effective therapy.
Robotic partial nephrectomy
Robot-assisted partial nephrectomy for kidney tumours.
Focal therapy for prostate cancer
Treating only the tumour area within the prostate.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
PSMA[tiab] AND PET[tiab] AND prostate[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.